Development of IG-100 (dasatinib), an inhibitor of multiple signaling kinases in a Phase 2a study which will be the first time that dasatinib is administered to NS and NSML pediatric patients with diagnosed HCM.

IGIA was founded in 2017 by a team of leading scientists with a combined century of experience in drug development, who are committed to the development of pharmaceutical products for the treatment of orphan indications or small population indications with an unmet medical need.